Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Acquired by Raymond James & Associates

Raymond James & Associates grew its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 122,144 shares of the company’s stock after purchasing an additional 4,342 shares during the period. Raymond James & Associates owned approximately 0.25% of Prestige Consumer Healthcare worth $8,807,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Opal Wealth Advisors LLC purchased a new stake in Prestige Consumer Healthcare in the second quarter valued at about $26,000. Quest Partners LLC increased its holdings in shares of Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after acquiring an additional 424 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 80.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after purchasing an additional 208 shares during the last quarter. Gladius Capital Management LP acquired a new stake in Prestige Consumer Healthcare in the 2nd quarter worth approximately $35,000. Finally, Northwestern Mutual Wealth Management Co. grew its position in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analysts Set New Price Targets

PBH has been the subject of a number of research analyst reports. DA Davidson raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Stock Down 0.1 %

PBH stock opened at $73.53 on Wednesday. The company has a market capitalization of $3.64 billion, a P/E ratio of 17.98, a price-to-earnings-growth ratio of 2.06 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 12 month low of $56.61 and a 12 month high of $75.80. The firm’s fifty day simple moving average is $71.91 and its 200-day simple moving average is $69.42. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.86 by $0.04. The company had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm’s revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.06 earnings per share. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.